PMID- 20874498
OWN - NLM
STAT- MEDLINE
DCOM- 20110328
LR  - 20220309
IS  - 1557-7732 (Electronic)
IS  - 1080-7683 (Linking)
VI  - 26
IP  - 5
DP  - 2010 Oct
TI  - Effectiveness of dorzolamide-timolol (COSOPT) in patients who were treatment 
      naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line 
      study.
PG  - 503-11
LID - 10.1089/jop.2010.0032 [doi]
AB  - PURPOSE: The aim of this study was to assess the effectiveness of 
      dorzolamide-timolol (DT) in the management of open-angle glaucoma (OAG) and 
      ocular hypertension. METHODS: An open-label, 12-week, multicenter, Canadian study 
      was conducted. Patients with untreated OAG or ocular hypertension received DT for 
      12 weeks to reduce intraocular pressure (IOP). If target IOP was not reached 
      after the first 6-week treatment period, a prostaglandin (PG) (latanoprost) was 
      added for the remaining 6 weeks. Primary outcome measures were changes in IOP 
      from baseline to 6 and 12 weeks of treatment, and secondary outcome measures 
      included the proportion of patients achieving target IOP and the proportion of 
      patients achieving therapeutic response defined as a reduction of 5.0 mmHg or 20% 
      in IOP from baseline. IOP values were the mean of 2 measures taken before and at 
      least 2 h after patients administered the study medication. RESULTS: A total of 
      164 patients were enrolled. Mean [standard deviation (SD)] population age was 
      63.0 (12.3) years and 53.0% of the patients were men. At week 6, the mean (SD) 
      absolute and percent change in IOP for the total population was (-11.1) (4.9) and 
      (-36.4)% (13.9%), respectively, and 92.1% of the patients achieved a reduction in 
      IOP of at least 5 mmHg. Therapeutic target was achieved by 136 (82.9%) patients 
      (DT subgroup) at 6 weeks, whereas 28 (17.1%) patients were changed to a 
      combination therapy of DT and latanoprost [DT plus PG (DT & PG) subgroup]. 
      Between weeks 6 and 12, DT was effective in sustaining the IOP within therapeutic 
      target, whereas addition of latanoprost reduced the IOP of the DT & PG subgroup 
      by an additional 6.3 mmHg or 22.1% (20.1%). At week 12, patients in the DT 
      subgroup experienced a clinically and statistically significant mean (SD) 
      decrease in IOP from a baseline of 12.2 mmHg or 40.4% (11.9%) (P < 0.001), 
      whereas these values corresponded to 13.4 mmHg and 39.7% (15.7%) (P < 0.001), 
      respectively, in the DT & PG subgroup. The proportion of patients who achieved 
      therapeutic response during the entire 12-week study period was over 82%. 
      Treatment-related adverse events (AEs) were reported by 19 (14.0%) patients in 
      the DT subgroup and by 6 (21.4%) patients in the combination subgroup. Eye 
      disorders and nervous system disorders were among the most common 
      treatment-related AEs in both subgroups. No serious AEs were reported during the 
      study period. CONCLUSION: DT alone and DT in combination with a PG are effective 
      in significantly reducing IOP in patients with untreated OAG or ocular 
      hypertension. The treatment was safe and well tolerated with a low incidence of 
      AEs.
FAU - Crichton, Andrew C S
AU  - Crichton AC
AD  - Faculty of Medicine, University of Calgary , Calgary, Canada.
FAU - Harasymowycz, Paul
AU  - Harasymowycz P
FAU - Hutnik, Cindy M L
AU  - Hutnik CM
FAU - Behki, Rama
AU  - Behki R
FAU - Boucher, Serge
AU  - Boucher S
FAU - Ibrahim, Fahim
AU  - Ibrahim F
FAU - Rifkind, Aaron W
AU  - Rifkind AW
FAU - Solomon, Leon
AU  - Solomon L
FAU - Liao, Chuanhong
AU  - Liao C
FAU - Bastien, Natacha R
AU  - Bastien NR
FAU - Sampalis, John S
AU  - Sampalis JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Ocul Pharmacol Ther
JT  - Journal of ocular pharmacology and therapeutics : the official journal of the 
      Association for Ocular Pharmacology and Therapeutics
JID - 9511091
RN  - 0 (Drug Combinations)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (Prostaglandins F, Synthetic)
RN  - 0 (Sulfonamides)
RN  - 0 (Thiophenes)
RN  - 0 (dorzolamide-timolol combination)
RN  - 6Z5B6HVF6O (Latanoprost)
RN  - 817W3C6175 (Timolol)
SB  - IM
MH  - Aged
MH  - Drug Combinations
MH  - Eye/physiopathology
MH  - Female
MH  - Glaucoma/drug therapy
MH  - Glaucoma, Open-Angle/*drug therapy
MH  - Humans
MH  - Intraocular Pressure/drug effects
MH  - Latanoprost
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Ocular Hypertension/*drug therapy
MH  - Ophthalmic Solutions/administration & dosage/pharmacology
MH  - Prostaglandins F, Synthetic/administration & dosage/adverse effects/*pharmacology
MH  - Sulfonamides/adverse effects/*pharmacology
MH  - Thiophenes/adverse effects/*pharmacology
MH  - Timolol/adverse effects/*pharmacology
MH  - Tonometry, Ocular
MH  - Treatment Outcome
EDAT- 2010/09/30 06:00
MHDA- 2011/03/29 06:00
CRDT- 2010/09/30 06:00
PHST- 2010/09/30 06:00 [entrez]
PHST- 2010/09/30 06:00 [pubmed]
PHST- 2011/03/29 06:00 [medline]
AID - 10.1089/jop.2010.0032 [doi]
PST - ppublish
SO  - J Ocul Pharmacol Ther. 2010 Oct;26(5):503-11. doi: 10.1089/jop.2010.0032.